This addition to Biomica's scientific expertise will support
the company's upcoming steps in its immuno-oncology clinical
development program
REHOVOT, Israel, July 28,
2022 /PRNewswire/ -- Biomica Ltd., a clinical-stage
biopharmaceutical company developing innovative microbiome-based
therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN)
(TASE: EVGN), today announced that Professor Gal Markel, Director
of the Davidoff Cancer Center & Deputy Director General of the
Rabin Medical Center at Clalit Health Services in Israel, is joining Biomica's Scientific
Advisory Board.
Professor Markel is an internationally recognized expert in
translational tumor immunology and clinical immuno-oncology. He
brings a wealth of knowledge, as an expert in clinical and
investigational Immuno-Oncology with broad experience in
integrative platforms. He is Professor of Tumor Immunology in the
Faculty of Medicine at Tel-Aviv
University. He is the author of more than 130 peer-reviewed
papers and the inventor of more than 20 patents. Prof. Markel
co-founded BTC (acquired by DSPG in 2011), was the scientific
founder and Chief Scientific Officer of cCAM Biotherapeutics
(acquired by Merck & Co in 2015) and 4C Biomed. He holds a PhD
and MD from the Hebrew University, an
MBA from the IDC and medical oncology training at Sheba Medical
Center.
In addition, Professor Markel was the principal investigator of
a groundbreaking investigator-initiated study, which demonstrated
for the first time, that melanoma immunotherapy can be successfully
boosted by changing the gut microbiome (via Fecal Microbiota
Transplantation). In this trial, it was shown that some patients
with metastatic melanoma refractory to immunotherapy, had an
objective tumor regression if immunotherapy was paired with a
microbiome therapy from a metastatic melanoma donor who had
achieved a complete response on immunotherapy. Professor Markel was
the senior and corresponding author of the article published in
Science on December 2021,
depicting the results of this trial.
Professor Gal Markel said: "I am very excited to join
Biomica's superb team and contribute to the development of its
unique microbiome-based therapeutics for cancer patients. I am
looking forward to embarking on this fantastic joint journey."
Professor Yehuda Ringel, CSO
and Chairman of the Scientific Advisory Board, commented: "I am
very pleased that Professor Markel has chosen to join our advisory
board. As an internationally renowned expert in the immune-oncology
field, I am convinced he will be an invaluable asset and strong
contributor to Biomica and its future success. I wholeheartedly
welcome Gal to Biomica and look forward to working closely with
him."
About Biomica
Biomica is a clinical-stage biopharmaceutical company developing
innovative microbiome-based therapeutics utilizing a dedicated
Computational Predictive Biology platform (CPB), licensed from
Evogene Ltd. Biomica aims to identify and characterize
disease-related microbiome entities and to develop novel
therapeutics based on these understandings. The company is focused
on the development of therapies for antibiotic resistant bacteria,
immuno-oncology, and microbiome-related gastrointestinal (GI)
disorders. Biomica is a subsidiary of Evogene Ltd. (NASDAQ: EVGN,
TASE: EVGN). For more information, please
visit www.biomicamed.com.
Contacts:
Lital
Mamon
Head of Marketing and PR
E: IR@evogene.com
T: +972-8-931-2097
Kenny Green
US Investor
Relations
E: IR@evogene.com
T: +1 212 378 8040
View original
content:https://www.prnewswire.com/news-releases/biomica-appoints-professor-gal-markel-to-companys-scientific-advisory-board-301595199.html
SOURCE Biomica Ltd.